Consumers use wellness apps, AI, and health trackers, giving them a false sense of being informed about their health. This creates a new gap where feeling well or having data is substituted for actual clinical evaluation, delaying necessary medical care, especially for silent diseases.
Brands often focus on market share against direct competitors. However, the real competition can be invisible factors like a patient's belief system, inertia, or logistical hurdles in the healthcare system that cause them to delay or abandon treatment altogether.
Companies excel at tracking post-diagnosis activities like script fills and adherence but often lack insight into the top of the funnel. They don't sufficiently analyze why potential patients delay seeking care, rely on wellness tools, or drop out of the system before ever receiving a diagnosis.
Most patient non-compliance is an intentional choice, not simply forgetfulness. Instead of using clinical terms like 'adherence,' pharma brands should adopt consumer-centric concepts like 'loyalty' and 'progress,' borrowing behavioral change tactics from wellness apps to keep patients motivated.
The traditional 6-9 month annual planning process in pharma is ill-equipped to handle accelerating consumer trends like AI-driven self-diagnosis and telemedicine. Brands must adopt a more agile strategy, using dedicated 'marketing R&D' budgets for continuous pilots to test and learn.